Lipodystrophy
Lipodystrophy: Introduction
Lipodystrophy: A rare group of disorders that can be acquired or inherited and involves adipose tissue abnormalities. The disorder is characterized by varying degrees of loss of body fat. The three forms of the condition are: total lipodystrophy, partial lipodystrophy and localized lipodystrophy.
More detailed information about the symptoms,
causes, and treatments of Lipodystrophy is available below.
Symptoms of Lipodystrophy
See full list of 7
symptoms of Lipodystrophy
Treatments for Lipodystrophy
Read more about treatments for Lipodystrophy
Wrongly Diagnosed with Lipodystrophy?
Lipodystrophy: Deaths
Read more about Deaths and Lipodystrophy.
Types of Lipodystrophy
- Partial
- Congenital generalised
- Localised lipoatrophy
- Insulin lipoatrophy
- more types...»
See full list of 4
Types of Lipodystrophy
Lipodystrophy: Complications
Read more about complications of Lipodystrophy.
Causes of Lipodystrophy
See full list of 13
causes of Lipodystrophy
Read more about causes of Lipodystrophy.
More information about causes of Lipodystrophy:
Disease Topics Related To Lipodystrophy
Research the causes of these diseases that are similar to, or related to, Lipodystrophy:
Lipodystrophy: Research Doctors & Specialists
Research related physicians and medical specialists:
Other doctor, physician and specialist research services:
Latest Treatments for Lipodystrophy
See full list of 9
latest treatments for Lipodystrophy
Research about Lipodystrophy
Visit our research pages for current research about Lipodystrophy treatments.
Clinical Trials for Lipodystrophy
The US based website ClinicalTrials.gov lists information on both federally
and privately supported clinical trials using human volunteers.
Some of the clinical trials listed on ClinicalTrials.gov for Lipodystrophy include:
- A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth - This study is no longer recruiting patients (Current: 23 Nov 2006)
- HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) - This study is currently recruiting patients (Current: 23 Nov 2006) - Lamivudine,Stavudine,Didanosine,Zidovudine,Tenofovir,Abacavir,Efavirenz (EFV),Nevirapine,Indinavir,Saquinavir,Amprenavir,Ritonavir,Nelfinavir,Tipranavir,enfuvirtide (T20)
- Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy - This study is no longer recruiting patients (Current: 23 Nov 2006)
- Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance - This study is currently recruiting patients (Current: 23 Nov 2006) - Recombinant Human Growth Hormone,Rosiglitazone
- Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients - This study is no longer recruiting patients (Current: 23 Nov 2006) - nucleoside analogue sparing HAART regimen
- more trials...»
See full list of 52
Clinical Trials for Lipodystrophy
Statistics for Lipodystrophy
Lipodystrophy: Broader Related Topics
Types of Lipodystrophy
Lipodystrophy Message Boards
Related forums and medical stories:
User Interactive Forums
Read about other experiences, ask a question about Lipodystrophy, or answer someone else's question, on our message boards:
Definitions of Lipodystrophy:
A collection of rare conditions resulting from defective fat metabolism and characterized by atrophy of the subcutaneous fat. They include total, congenital or acquired, partial, abdominal infantile, and localized lipodystrophy.
- (Source - Diseases Database)
Lipodystrophy is listed as a "rare disease" by the Office of
Rare Diseases (ORD) of the National Institutes of Health
(NIH). This means that Lipodystrophy, or a subtype of Lipodystrophy,
affects less than 200,000 people in the US population.
Source - National Institutes of Health (NIH)
Contents for Lipodystrophy:
User Surveys and Discussion Forums
» Next page:
What is Lipodystrophy?
Medical Tools & Articles:
Tools & Services:
Medical Articles:
Forums & Message Boards
- Ask or answer a question at the Boards: